Home Cart Sign in  
Chemical Structure| 1010100-07-8 Chemical Structure| 1010100-07-8

Structure of CC-885
CAS No.: 1010100-07-8

Chemical Structure| 1010100-07-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-885 is a novel cereblon (CRBN) modulator that promotes the ubiquitination and degradation of GSPT1 by recruiting it to the CRL4(CRBN) E3 ubiquitin ligase complex. CC-885 holds potential application value in cancer research, particularly in tumors dependent on specific protein stability.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CC-885

CAS No. :1010100-07-8
Formula : C22H21ClN4O4
M.W : 440.88
SMILES Code : O=C(NCC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2)=O)C=C1)NC4=CC=C(C)C(Cl)=C4
MDL No. :MFCD31657329
InChI Key :DOEVCIHTTTYVCC-UHFFFAOYSA-N
Pubchem ID :24788636

Safety of CC-885

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CRBN

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 1 μM 24 h To assess the effect of CC-885 on BNIP3L-mediated mitophagy. Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254
HEK293T cells 1 μM 24 h To verify whether CC-885-induced BNIP3L protein degradation is CRBN-dependent. Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254
A549 cells 200 nM 12 h To identify potential neosubstrates of CC-885 in A549 cells using quantitative proteomics analysis. Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254
NCI-H1299 cells 50 nM 24 h This synergistic effect was also obtained in another NSCLC cell line, NCI-H1299. Mol Ther Oncolytics. 2020 Jun 23;18:215-225
A549 cells 50 nM 24 h CC-885 synergistically enhanced volasertib-induced cell death in NSCLC identified by IMiD drug screen. Mol Ther Oncolytics. 2020 Jun 23;18:215-225
U87 glioblastoma cells 100 nM 16 h To confirm the ubiquitination effect of CC-885 on GSPT1 via the E3 ubiquitin ligase complex (CRL4CBRN) Cell Death Dis. 2024 Aug 8;15(8):572
LX2 cells 1 μM 24 h To evaluate the inhibitory effect of CC-885 on BNC2 expression, results showed CC-885 significantly reduced BNC2 protein levels Nat Commun. 2022 Sep 10;13(1):5324
HDQ-P1 cells 10 nM 72 h CC-885 efficiently reduced eRF3a levels starting a few h after compound addition and reaching >90% reduction within 24h. Nucleic Acids Res. 2021 Apr 19;49(7):3692-3708

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/cA nude mice A549 xenograft model Intraperitoneal injection 20 mg/kg Three times per week for four weeks While volasertib and CC-885 alone inhibited tumor growth, the combination of both small molecular drugs markedly inhibited tumor growth and reduced tumor weights. Mol Ther Oncolytics. 2020 Jun 23;18:215-225
Nude mice U87 glioblastoma cell transplanted brain tumor model Intraperitoneal injection 50 mg/kg and 100 mg/kg Once every alternate day, total of 4 times To assess the therapeutic effect of CC-885 on transplanted brain tumors, showing significantly prolonged survival and reduced tumor size Cell Death Dis. 2024 Aug 8;15(8):572

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.34mL

2.27mL

1.13mL

22.68mL

4.54mL

2.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories